1. Home
  2. MMC vs REGN Comparison

MMC vs REGN Comparison

Compare MMC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marsh & McLennan Companies Inc.

MMC

Marsh & McLennan Companies Inc.

HOLD

Current Price

$181.80

Market Cap

90.9B

Sector

Finance

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$774.35

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMC
REGN
Founded
1871
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.9B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
MMC
REGN
Price
$181.80
$774.35
Analyst Decision
Buy
Buy
Analyst Count
14
23
Target Price
$215.31
$795.74
AVG Volume (30 Days)
2.5M
855.4K
Earning Date
01-29-2026
02-03-2026
Dividend Yield
1.94%
0.46%
EPS Growth
2.86
2.88
EPS
8.34
41.59
Revenue
$26,453,000,000.00
$14,247,800,000.00
Revenue This Year
$11.27
$1.99
Revenue Next Year
$5.00
$6.68
P/E Ratio
$22.25
$18.56
Revenue Growth
10.47
2.89
52 Week Low
$174.18
$476.49
52 Week High
$248.00
$792.77

Technical Indicators

Market Signals
Indicator
MMC
REGN
Relative Strength Index (RSI) 42.22 61.40
Support Level $183.92 $775.00
Resistance Level $188.50 $792.77
Average True Range (ATR) 2.14 13.49
MACD -0.10 -1.42
Stochastic Oscillator 3.50 69.19

Price Performance

Historical Comparison
MMC
REGN

About MMC Marsh & McLennan Companies Inc.

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: